Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Projected Valuation Of The Influenza Treatment Market In The Coming Years?

In the past few years, the size of the influenza treatment market has been experiencing consistent growth. It’s predicted to escalate from $6.6 billion in 2024 to $6.83 billion in 2025, recording a compound annual growth rate (CAGR) of 3.4%. The expansion recorded during the historic period can be linked to an upsurge in annual influenza cases, augmented government financial support for influenza studies and readiness programs, campaigns to raise public awareness about vaccination, the development of international influenza monitoring systems, and an increase in healthcare facilities.

In the upcoming years, the influenza treatment market is projected to enjoy consistent growth, eventually reaching $7.93 billion in 2029 with a compound annual growth rate (CAGR) of 3.8%. This growth during the forecast period can be linked to the debut of novel antiviral medications and treatment techniques, enhanced vaccination initiatives, the continued evolution and refinement of healthcare facilities, a growing over-aged population, and the formulation of innovative therapies. Noteworthy trends for this forecast period extend to strides made in the creation of universal vaccines, breakthroughs in vaccine distribution models, the fusion of AI and voluminous data, progress in individualized medicinal approaches, and heightened partnership activities among pharmaceutical corporations.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15832&type=smp

Which Industry Forces Are Driving The Influenza Treatment Market Forward?

The surge in contagious respiratory diseases is anticipated to be a major propellant for the growth of the influenza treatment market. Infectious diseases such as influenza, measles, or respiratory syncytial virus (RSV) infections fall under the category of contagious respiratory illnesses. They spread through contact with an infected person, their bodily fluids, or through contaminated objects or surfaces. The expansion of these diseases is associated with a high density of population, insufficient healthcare framework, antibiotic misuse, and the ease of international travel. Influenza treatments, which encompass antiviral drugs and vaccines, are utilized to address various contagious respiratory diseases like the flu, COVID-19, and other respiratory viruses. The Centers for Disease Control and Prevention (CDC), a national public health agency based in the United States, reported that in September 2023, hospital admissions due to RSV (Respiratory Syncytial Virus) increased from 2 per 100,000 people in the week ending on August 5, 2023, to 7 per 100,000 populace by the week concluding on August 19, 2023. This rise in contagious respiratory diseases underscores the reasons behind the escalating growth of the influenza treatment market.

What Are The Primary Segmentation Parameters In The Influenza Treatment Market?

The influenza treatment market covered in this report is segmented –

1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products

2) By Route Of Administration: Oral, Other Routes Of Administration

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:

1) By Peramivir: Intravenous Peramivir, Peramivir Injection

2) By Zanamivir: Inhaled Zanamivir, Zanamivir Diskhaler

3) By Oseltamivir Phosphate: Oseltamivir Capsules, Oseltamivir Oral Suspension

4) By Baloxavir Marboxil: Baloxavir Tablets, Baloxavir Granules For Oral Suspension

5) Other Products: Rimantadine, Amantadine

Which Emerging Trends Are Reshaping The Influenza Treatment Market Landscape?

Leading corporations in the influenza treatment market are concentrating on broadening their product offerings by introducing novel solutions like single-dose oral drugs for flu treatment. The goal is to increase patient adherence, enhance treatment results, and seize a larger portion of the market. A single-dose oral medication is a drug aimed at treating the flu through a single oral dose, making the treatment process less complicated. For example, Genentech Inc., a biotechnology firm from the U.S., declared in August 2022 that the U.S. Food and Drug Administration (FDA) granted approval for Xofluza (Baloxavir Marboxil). Xofluza signifies a pioneering single-dose oral medicine, providing a convenient and efficient means to manage acute uncomplicated influenza in children from five to less than 12 years, who’ve shown symptoms for no longer than 48 hours, and other respiratory illnesses.

Which Players Are Shaping The Competitive Landscape Of The Influenza Treatment Market?

Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

What Are The Emerging Regional Trends Driving The Influenza Treatment Market?

North America was the largest region in the influenza treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15832&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model